Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Cost of Revenue (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Cost of Revenue for 16 consecutive years, with $48000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cost of Revenue fell 73.18% to $48000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$17.7 million, a 179.76% decrease, with the full-year FY2024 number at $1.6 million, down 93.3% from a year prior.
  • Cost of Revenue was $48000.0 for Q3 2025 at Harvard Bioscience, down from $9.2 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $13.4 million in Q3 2021 to a low of -$27.2 million in Q4 2024.
  • A 5-year average of $2.6 million and a median of $5.8 million in 2022 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: surged 141.48% in 2023, then crashed 540.91% in 2024.
  • Harvard Bioscience's Cost of Revenue stood at -$13.1 million in 2021, then dropped by 13.47% to -$14.9 million in 2022, then soared by 141.48% to $6.2 million in 2023, then plummeted by 540.91% to -$27.2 million in 2024, then surged by 100.18% to $48000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Cost of Revenue are $48000.0 (Q3 2025), $9.2 million (Q2 2025), and $264000.0 (Q1 2025).